Alexis Borisy and Melanie Nallicheri
October 4, 2023 05:12 PM EDTUpdated 05:42 PM
Deals

EQRx had lim­it­ed buy­er in­ter­est, tried ac­quir­ing oth­er com­pa­nies be­fore Rev­o­lu­tion came for its cash

Kyle LaHucik

Senior Reporter

In No­vem­ber, EQRx pub­licly gave up on the fi­nal pieces of its low-cost med­i­cines ap­proach. But in a re­cent fi­nan­cial

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times